New Delhi: Suven Life Sciences on Friday said it has received five product patents for its drug in Europe, Hong Kong, Israel, Australia and Norway for the treatment of disorders associated with neuro-degenerative diseases.
"The grant of 1 product patent from Australia, one from Europe, one from Hong Kong, one from Israel and one from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases," Suven Life Sciences said in a filing to the BSE.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven, it added.
The compounds are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, it said.
With these new patents, Suven has a total of 21 granted patents from Australia, 15 from Europe, 16 from Hong Kong, four from Israel and five from Norway.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the firm said.
Shares in Suven Life Sciences, on Friday, ended at Rs 296.90 apiece on the BSE, down 1.10 per cent from the previous close.